Search

everythinglearnresearchcommunity

for

Search:↓

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

A user experienced increased estradiol, nipple tenderness, and ED after taking finasteride. They are considering dose reduction to mitigate these effects.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

The conversation discusses the potential benefits of adding Vitamin B6 (P-5-P) to topical hair loss treatments like RU58841, finasteride, or minoxidil. The user suggests that Vitamin B6 might enhance these treatments by naturally lowering scalp prolactin.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

A user who has been using Pyrilutamide for 5 months with no results, and other users suggesting they switch to RU58841 or stick to their treatment plan for at least one year.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

Using Pyrilutamide or RU as monotherapy for hair loss? Share experiences.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

The user has accepted their hair loss and uses finasteride and minoxidil, with past use of RU58841 and dutasteride. They seek advice on supplements to slow down graying hair.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

The effectiveness of pyrilutamide, a hair loss treatment, with research results being postponed until September. Various people shared their experiences with topical finasteride, minoxidil and RU58841, as well as other treatments such as dandruff shampoo, group buys and grey markets.

A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The user is using minoxidil and recently started fluridil for mild hair loss and is questioning if this treatment is sufficient without finasteride. They have finasteride available but prefer not to use it.

A user discusses switching from RU58841 to Pyrilutamide due to side effects like fatigue, brain fog, and elevated heart rate. They have used dutasteride, finasteride, and minoxidil, and are seeking safer alternatives.

User tries Fluridil for hair loss after topical finasteride caused issues. Others doubt its effectiveness and cost.

The user experienced side effects from finasteride and is considering adding Alfatradiol or Fluridil to their regimen, which includes Minoxidil, dermarolling, and ketoconazole. Fluridil is noted to be more effective than Alfatradiol but less effective than finasteride, with mild side effects reported.

The user is experiencing side effects from fluridil after switching from finasteride due to severe side effects. They are uncertain whether to continue with fluridil, considering it might be their body adjusting, a nocebo effect, or a permanent issue.

The conversation discusses switching from oral finasteride to topical RU58841 for hair loss, with concerns about hormonal effects and libido. Some users suggest alternatives like dutasteride, while others share mixed experiences with RU58841's effectiveness.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

The conversation is about the potential effectiveness of a hair loss treatment called pyrilutamide. One person has been using it since September and reports positive results.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.